Latest News and Press Releases

SHANGHAI and CAMBRIDGE, Mass., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), today announced that members of the company’s senior management team will participate in...

SHANGHAI and CAMBRIDGE, Mass., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the Center for Drug Evaluation (CDE) of China’s National Medical...

SHANGHAI and CAMBRIDGE, Mass., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today...

SHANGHAI and CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that Michel Vounatsos has been appointed to its Board of Directors,...

The LUNAR study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in overall survival The full LUNAR data will be presented at a future...

SHANGHAI and CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today...

SHANGHAI, China and CAMBRIDGE, Mass., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company,...

-   Median overall survival (mOS) was numerically longer for patients receiving ZEJULA regardless of biomarker status, at 46.3 months compared to 43.4 months in the placebo group-   No new safety...

Adagrasib in combination with pembrolizumab demonstrates favorable tolerability and promising preliminary efficacy in patients with first-line advanced/metastatic NSCLC harboring a KRASG12C...

Revenue of $57.5 million for the third quarter of 2022, representing a 33% increase y-o-y and a 19% increase q-o-q; continued revenue growth led by ZEJULA Regional strategic...